WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012098237) COMPOUNDS WITH SUPER-ASPIRIN EFFECTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/098237    International Application No.:    PCT/EP2012/050888
Publication Date: 26.07.2012 International Filing Date: 20.01.2012
IPC:
C07D 493/04 (2006.01), A61K 31/34 (2006.01), A61P 29/00 (2006.01), A61P 35/00 (2006.01)
Applicants: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN [IE/IE]; Trinity College Dublin University Dublin, 2 (IE) (For All Designated States Except US).
GILMER, John Francis [IE/IE]; (IE) (For US Only).
LEDWIDGE, Mark [IE/IE]; (IE) (For US Only).
O'FLYNN, Pat [IE/IE]; (IE) (For US Only).
HARMON, Shona [IE/IE]; (IE) (For US Only).
RADOMSKI, Marek [PL/IE]; (IE) (For US Only).
MARTIN, Carlos Medina [ES/IE]; (IE) (For US Only).
SOLVOTRIN THERAPEUTICS LTD [IE/IE]; Hoffman Park, Inchera, Little Island, Cork (IE) (For All Designated States Except US)
Inventors: GILMER, John Francis; (IE).
LEDWIDGE, Mark; (IE).
O'FLYNN, Pat; (IE).
HARMON, Shona; (IE).
RADOMSKI, Marek; (IE).
MARTIN, Carlos Medina; (IE)
Agent: GAFFNEY, Naoise Eoin; Tomkins & Co 5 Dartmouth Road Dublin, 6 (IE)
Priority Data:
2011/0025 21.01.2011 IE
Title (EN) COMPOUNDS WITH SUPER-ASPIRIN EFFECTS
(FR) COMPOSÉS AVEC DES EFFETS DE SUPER-ASPIRINE
Abstract: front page image
(EN)A compound having the structural formula (I) and pharmaceutically acceptable salt and/or hydrates thereof, (I) wherein Y is an arylester or an C1– C8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, -Cl, -Br, a C1– C8 alkyl, benzyl, a C1– C8 alkoxy, benzyloxy, -NHC(O)R, -NH2, -NO2,-ONO2, –(CH2)n ONO2, –OC(O)[(CH2)m]cyclic ONO2, -OCOArONO2,-OCOAr (CH2)n ONO2 or a C1– C5 haloalkyl ester, wherein R is a C1– C8 alkyl or a C1– C8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.
(FR)La présente invention concerne un composé ayant la formule structurale (I) et un sel pharmaceutiquement acceptable et/ou des hydrates de celui-ci, (I) dans laquelle Y est un ester d'aryle ou un ester d'alkylaryle en C1-C8, choisi dans le groupe constitué de : benzène, toluène, xylène, acide benzoïque, benzoate, nicotinate, isonicotinate et halogénobenzène, qui peut être non substitué ou substitué par au moins un groupe libérant de l'oxyde nitrique; et/ou au moins l'un parmi hydroxyde, -Cl, -Br, un alkyle en C1-C8, benzyle, un alcoxy en C1-C8, benzyloxy, -NHC(O)R, -NH2, -NO2,-ONO2, -(CH2)nONO2, -OC(O)[(CH2)m]cycliqueONO2, -OCOArONO2,-OCOAr(CH2)nONO2 ou un ester d'halogénalkyle en C1-C5, R étant un groupe alkyle en C1-C8 ou alcoxy en C1-C8, n = 1 à 8 et m = 3 à 10, pour produire un effet de super-aspirine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)